2. Signaling Pathways
  3. Immunology/Inflammation
  4. FAP

FAP

Fibroblast activation protein

Fibroblast activation protein (FAP) is a cell-surface serine protease that acts on various hormones and extracellular matrix components. FAP is highly upregulated in a wide variety of cancers, and is often used as a marker for pro-tumorigenic stroma.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P11599
    NOTA-SP2A-FAPT
    		Ligand
    NOTA-SP2A-FAPT is a fibroblast activation protein (FAP) ligand. NOTA-SP2A-FAPT can be adiolabeled and exhibits rapid renal excretion with fast kidney tissue clearance, accumulates rapidly in and retains high levels in FAP-positive tumor xenografts to enable clear tumor visualization. NOTA-SP2A-FAPT can be used as a tracer of cancer.
    NOTA-SP2A-FAPT
  • HY-P10945A
    Cys-FAP targeting peptide for FXX489
    Cys-FAP targeting peptide for FXX489 is the polypeptide part of Unlabeled FXX489 (HY-P10944). Unlabeled FXX489 is a fibroblast activation protein (FAP)-targeting ligand.
    Cys-FAP targeting peptide for FXX489
  • HY-P11602
    DOTA-C1-FAP-2286
    DOTA-C1-FAP-2286 is a cysteic acid-modified fibroblast activation protein (FAP)-targeting radioligand. DOTA-C1-FAP-2286 binds competitively to FAP with an IC50 of 127.64 nM. DOTA-C1-FAP-2286 is targeted accumulation in FAP-expressing cells and exhibits accelerated renal clearance. DOTA-C1-FAP-2286 can be used as a PET/CT tracer in cancer.
    DOTA-C1-FAP-2286
  • HY-175330
    FAP-IN-6
    		Inhibitor
    FAP-IN-6 (Compound 21) is a selectivity FAP inhibitor with an IC50 of 13 pM. FAP-IN-6 has a high metabolic stability. FAP-IN-6 labeled with 18F can be used as a positron emission tomography (PET) tracer. FAP-IN-6 can be used for microenvironment of cancers research.
    FAP-IN-6
  • HY-175322
    FAPI-P8PN
    		Inhibitor
    FAPI-P8PN is a fibroblast activation protein (FAP) inhibitor (IC50=3.6 nM). FAPI-P8PN is promising for research of FAP-overexpressing solid tumors.
    FAPI-P8PN
  • HY-177083
    Faridoxorubicin
    		Substrate
    Faridoxorubicin (AVA-6000) is a prodrug targeting fibroblast activation protein α (FAPα). Faridoxorubicin releases active doxorubicin through FAPα-mediated cleavage, enhancing intratumoral drug exposure and reducing cardiac toxicity. Faridoxorubicin is promising for research of solid tumors (e.g., colorectal cancer liver metastasis).
    Faridoxorubicin
  • HY-178981
    FAP-IN-8
    		Inhibitor
    FAP-IN-8 (Compound 12i) is a potent inhibitor of PREP and FAP, with pIC50 values ​​of 8.99 and 10.08 for FAP and PREP, and IC50 values ​​of 1 and 0.08 nM, respectively. FAP-IN-8 may be used in cancer research.
    FAP-IN-8
  • HY-148361
    Fluorogen binding modulator-1
    Fluorogen binding modulator-1 (PubChem SID 125240934) is a fluorogen activating protein (FAP)-fluorogen binding modulator with -log EC50s of 6.61 and 6.37 for AM2.2-β2AR and AM2.2-GPR32, respectively.
    Fluorogen binding modulator-1
  • HY-175685
    FAP-IN-7
    		Inhibitor
    FAP-IN-7 (Compound 5b) is a FAP
    FAP-IN-7
  • HY-159771
    FAP6-19
    		Ligand
    FAP6-19 is a fibroblast activation protein (FAP) targeting radioligand with a Kd of 18.2 nM. FAP6-19 selectively delivers therapeutic radioactive nuclides (such as 177Lu) to the tumor site by targeting the overexpressed FAP protein in the tumor microenvironment, achieving precise killing of cancer cells while minimizing radiation damage to healthy tissues. FAP6-19 exhibits extremely high total cellular uptake and good intracellular retention ability in HT1080 cells. After being labeled with 111In, FAP6-19 produced extremely high tumor/kidney and tumor/liver dose ratios in the mouse model with 4T1 tumors. FAP6-19 can be used in the research of solid tumors expressing FAP.
    FAP6-19
  • HY-182250
    BR103354
    		Inhibitor
    BR103354 is an orally active, selective fibroblast activation protein (FAP) inhibitor with an IC50 value of 14 nM against hFAP. BR103354 restores the levels of phosphorylated ERK and Glut1 that are reduced by co-treatment with hFGF21 and FAP, decreases non-fasting blood glucose concentrations, improves glucose tolerance, and reduces hepatic triglyceride content. BR103354 ameliorates hepatic steatosis and hepatic fibrosis. BR103354 can be used in the research of type 2 diabetes and non-alcoholic steatohepatitis.
    BR103354
  • HY-170779
    DOTA-NI-FAPI-04
    		Inhibitor
    DOTA-NI-FAPI-04 is a FAP inhibitor (IC50 = 7.44 nM). By integrating FAP targeting with hypoxia-sensitive groups (nitroimidazole), DOTA-NI-FAPI-04 significantly enhances tumor uptake and retention capabilities. DOTA-NI-FAPI-04 chelates metallic isotopes (such as 68Ga and 177Lu) through DOTA to produce radioactive probes ([68Ga]Ga/DOTA-NI-FAPI-04 and [177Lu]Lu/DOTA-NI-FAPI-04), which can be used for research in tumor diagnostics and therapeutic agents. DOTA-NI-FAPI-04 holds dual targeting potential in the fields of cancer imaging, tumor microenvironment analysis, and radionuclide therapy, particularly suitable for scenarios where the tumor stroma and hypoxic regions synergistically interact.
    DOTA-NI-FAPI-04
  • HY-146182
    FSDD3I
    FSDD3I is an albumin-binding fibroblast activation protein (FAP) ligand. FSDD3I can be labeled with 68Ga and 177Lu for single photon emission computed tomography (SPECT) imaging.
    FSDD3I
  • HY-175353
    TriOncoFAP-GlyPro-MMAE
    TriOncoFAP-GlyPro-MMAE is a small molecule drug conjugate (SMDC) targeting fibroblast activation protein (FAP) with an IC50 of 13 pmol/L. TriOncoFAP-GlyPro-MMAE combines a FAP-targeting ligand (TriOnco), a cleavable glycine-proline linker, and a cytotoxic payload (MMAE).
    TriOncoFAP-GlyPro-MMAE
  • HY-176958
    OncoFAP-EN-DOTAGA
    		Inhibitor
    OncoFAP-EN-DOTAGA is a FAP (fibroblast activation protein) targeting conjugate compound. OncoFAP-EN-DOTAGA can chelate radioactive isotopes (such as ) Ga-68 or fluorescent agent and can be used as a probe with targeting binding functions.
    OncoFAP-EN-DOTAGA
  • HY-183513
    L-Ala-BPA
    		Substrate
    L-Ala-BPA is a boron delivery agent. L-Ala-BPA is transported into tumor cells via PEPT1/2 and LAT-1 (SLC7A5) pathways and is rapidly cleaved systemically by endogenous proteases including FAP to yield L-BPA (HY-W087830). L-Ala-BPA shows antitumor activity and can be used for the research of Boron Neutron Capture Therapy (BNCT).
    L-Ala-BPA
  • HY-P3392
    Zilganersen
    Zilganersen (ION373) is a gapmer antisense oligonucleotide targeting glial fibrillary acidic protein (GFAP). Zilganersen reduces excess glial fibrillary acidic protein produced by disease-causing variants in the GFAP gene and inhibits synthesis of GFAP. Zilganersen can be used for the research of Alexander disease.
    Zilganersen
  • HY-186190
    I-FAPI-04 prodrug-1
    		Inhibitor
    I-FAPI-04 prodrug-1 is a prodrug of I-FAPI-04, which is an inhibitor targeting fibroblast activation protein (FAP). I-FAPI-04 prodrug-1 can be used as a radioactive tracer in cancer.
    I-FAPI-04 prodrug-1
  • HY-100684R
    UAMC-1110 (Standard)
    		Inhibitor
    UAMC-1110 (Standard) is the analytical standard of UAMC-1110 (HY-100684). This product is intended for research and analytical applications. UAMC-1110 is a highly potent and selective inhibitor of fibroblast activation protein (FAP) with an IC50 of 3.2 nM. UAMC-1110 also inhibits prolyl oligopeptidase (PREP) with an IC50 of 1.8 μM.
    UAMC-1110 (Standard)
  • HY-181580
    FAP Ligand 3
    		Ligand
    FAP Ligand 3 is a FAP ligand with a Ki value of 0.092 nM. FAP Ligand 3 acts as a tumor-retaining agent and serves as a FAP-targeted positron emission tomography (PET) tracer for tumor imaging. FAP Ligand 3 is applicable to studies related to glioma.
    FAP Ligand 3
Cat. No. Product Name / Synonyms Application Reactivity